The University of Western Australia

Benralizumab Shows Promise as Novel Treatment for Asthma and COPD Flare-Ups

6 months ago

• A recent clinical trial reveals benralizumab, a monoclonal antibody, significantly reduces respiratory symptoms during asthma and COPD flare-ups, outperforming traditional steroid treatments. • The study demonstrated that benralizumab led to four times fewer treatment failures compared to prednisolone, marking a potential shift in managing these conditions. • Benralizumab targets eosinophils, key contributors to lung inflammation, offering a more precise approach with fewer side effects than conventional steroids. • Researchers are optimistic about benralizumab's potential for home or GP administration, pending further trials to confirm its efficacy and cost-effectiveness.